Clinical Trial Supplies Market to Reach $8.95 Billion by 2031

The global market for clinical trial supplies is projected to reach $8.95 billion by 2031, up from an estimated $5.60 billion in 2026. The market is expected to grow at a compound annual growth rate (CAGR) of 8.9% during the forecast period.

North America currently leads the market, accounting for over 41.4% of global revenue in 2025. This dominance is attributed to significant research and development spending in the pharmaceutical and biotechnology sectors, extensive clinical trial activity, and a well-established infrastructure for supply depots and service providers.

Logistics and distribution services held the largest share of the market in 2025, representing 27.2%. Growth in this segment is driven by the rise of multinational and decentralized trials, along with an increasing volume of temperature-sensitive biologics, vaccines, and advanced therapies requiring validated cold-chain transportation and direct-to-patient distribution.

Small molecules constituted the largest segment by product type, making up approximately 59.9% of the market in 2025. This is supported by a large number of small-molecule drug candidates in development, established manufacturing processes, and ongoing demand for oral solid dosage forms.

The market's expansion is fueled by an increasing number of clinical trials, higher R&D investments, and the adoption of decentralized and adaptive study designs. Oncology remained the leading therapeutic area in 2025, increasing the demand for specialized supply chain management, cold-chain logistics, and comparator drug sourcing.